Efficacy and safety of olodaterol once daily delivered via Respimat^® in patients with GOLD 2–4 COPD: results from two replicate 48-week studies

References

• TashkinDPFergusonGTCombination bronchodilator therapy in the management of chronic obstructive pulmonary diseaseRespir Res2013144923651244
   PubMed Web of Science ®Google Scholar
• Global Initiative for Chronic Obstructive Lung DiseaseGlobal strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated 2013 Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfAccessed July 15, 2013
   Google Scholar
• TashkinDPCelliBSennSA 4-year trial of tiotropium in chronic obstructive pulmonary diseaseN Engl J Med2008359151543155418836213
   PubMed Web of Science ®Google Scholar
• DahlRGreefhorstLAPMNowakDInhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med2001164577878411549532
   PubMed Web of Science ®Google Scholar
• CazzolaMSantangeloGPiccoloAEffect of salmeterol and formoterol in patients with chronic obstructive pulmonary diseasePulm Pharmacol1994721031077915921
   PubMedGoogle Scholar
• CazzolaMMateraMGNovel long-acting bronchodilators for COPD and asthmaBr J Pharmacol2008155329129918604231
   PubMed Web of Science ®Google Scholar
• ToyELBeaulieuNUMcHaleJMTreatment of COPD: relationships between daily dosing frequency, adherence, resource use, and costsRespir Med2011105343544120880687
   PubMed Web of Science ®Google Scholar
• BouyssouTCasarosaPNalineEPharmacological characterization of olodaterol, a novel inhaled β2-adrenoceptor agonist exerting a 24-hour-long duration of action in preclinical modelsJ Pharmacol Exp Ther20103341536220371707
   PubMed Web of Science ®Google Scholar
• CasarosaPKollakIKiechleTFunctional and biochemical rationales for the 24-hour-long duration of action of olodaterolJ Pharmacol Exp Ther2011337360060921357659
   PubMed Web of Science ®Google Scholar
• BouyssouTHoenkeCRudolfKDiscovery of olodaterol, a novel inhaled β2-adrenoceptor agonist with a 24 h bronchodilatory efficacyBioorg Med Chem Lett20102041410141420096576
   PubMed Web of Science ®Google Scholar
• O’ByrnePMvan der LindeJCockcroftDWProlonged bronchoprotection against inhaled methacholine by inhaled BI 1744, a long-acting β2-agonist, in patients with mild asthmaJ Allergy Clin Immunol200912461217122120004781
   PubMed Web of Science ®Google Scholar
• O’ByrnePMD’UrzoTGahlemannMHartLWangFBeckEDose-finding study of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthmaAm J Respir Crit Care Med2012185A3963 (Abstract)
   Google Scholar
• van NoordJASmeetsJJDrenthBM24-hour bronchodilation following a single dose of the novel β2-agonist olodaterol in COPDPulm Pharmacol Ther201124666667221839850
   PubMed Web of Science ®Google Scholar
• JoosGAumannJLCoeckCKorduckiLHamiltonALvan NoordJComparison of 24-hour FEV1 profile for once-daily versus twice-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with COPDAm J Respir Crit Care Med2012185A2930 (Abstract)
   Google Scholar
• van NoordJAKorduckiLHamiltonAKokerPFour weeks once daily treatment with BI 1744 CL, a novel long-acting β2-agonist, is effective in COPD patientsAm J Respir Crit Care Med2009179A6183 (Abstract)
   Web of Science ®Google Scholar
• US Department of Health and Human Services, US Food and Drug Administration, Center for Drug Evaluation and Research (CDER)Guidance for industry. Chronic obstructive pulmonary disease: developing drugs for treatment. Draft guidance Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM071575.pdfAccessed April 26, 2012
   Google Scholar
• RedelmeierDAGuyattGHGoldsteinRSAssessing the minimal important difference in symptoms: a comparison of two techniquesJ Clin Epidemiol19964911121512198892486
   PubMed Web of Science ®Google Scholar
• MillerMRHankinsonJBrusascoVStandardisation of spirometryEur Respir J200526231933816055882
   PubMed Web of Science ®Google Scholar
• European Medicines AgencyStatistical principles for clinical trials Available from: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdfAccessed July 24, 2013
   Google Scholar
• McGarveyLKochASachsP48-week administration of olodaterol QD via Respimat® vs placebo and formoterol BID in patients with COPD: Pooled safety analysisEur Respir J201342Suppl 57749sP3633 (Abstract)
   Google Scholar
• TomlinsonBCruickshankJMHayesYSelective β-adrenoceptor partial agonist effects of pindolol and xamoterol on skeletal muscle assessed by plasma creatine kinase changes in healthy subjectsBr J Clin Pharmacol19903056656721980200
   PubMed Web of Science ®Google Scholar
• AlbertPAgustiAEdwardsLBronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary diseaseThorax201267870170822696176
   PubMed Web of Science ®Google Scholar
• KochAPaggiaroPHamiltonASymptomatic benefit of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: Combined analysis from two 48-week studiesEur Respir J201342Suppl 57145sP763 (Abstract)
   Google Scholar
• KochAPizzichiniEHamiltonALung function efficacy of olodaterol QD delivered via Respimat® vs placebo and formoterol BID in patients with COPD: two 48-week studiesEur Respir J201342Suppl 57146sP764 (Abstract)
   Google Scholar
• FergusonGTSachsPHamiltonATetzlaffKKorduckiLKochAEfficacy of olodaterol once daily (QD) via Respimat^® in GOLD 2/3 COPD patients not receiving background therapy: pooled data from 48-week studiesAbstract 727A presented at CHESTChicago, IL, USAOctober 26–31, 2013
   Google Scholar
• European Medicines AgencyGuideline on clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease (COPD) Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/08/WC500130880.pdfAccessed August 7, 2013
   Google Scholar
• DeromEWestermanJGrönkeLThe 24-hour lung function profile of once-daily tiotropium and olodaterol fixed-dose combination compared with placebo and monotherapies in chronic obstructive pulmonary disease (VIVACITO)Abstract D44 presented at American Thoracic SocietySan Diego, CA, USAMay 16–21, 2014
   Google Scholar
• LangePAumannJ-LDeromEThe 24-h FEV1 time profile of olodaterol QD delivered via Respimat® in COPD: results from two 6-week studiesEur Respir J201342Suppl 57982s4635 (Abstract)
   Google Scholar
• FeldmanGBernsteinJHamiltonANivensCWangFLaForceCThe 24-hour FEV₁time profile of olodaterol once daily (QD) via Respimat^® and formoterol twice daily (BID) via Aerolizer^® in patients with COPD: results from two 6-week studiesAbstract 749A presented at CHESTChicago, IL, USAOctober 26–31, 2013
   Google Scholar
• MaltaisFKirstenAHamiltonADe SousaDWangFDecramerMEvaluation of the effects of olodaterol on exercise endurance in patients with COPD: results from two 6-week studiesAbstract 748A presented at CHESTChicago, IL, USAOctober 26–31, 2013
   Google Scholar